phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of apo (a) FPIA and RIA results may be several, and have only partially been identified. For example, falsely high T4 results by FPIA have been reported to be caused by serum with high background fluorescence (3). Identification of the factors interfering with the FPIA determination ofT4 would be of interest because proper precautions such as modification of the assay could prevent the expensive and extensive patient work-up that has followed these spurious determinations (4). In this study, we identified a novel circulating antibody in a patient's serum that was responsible for falsely low T4 determinations by the FPIA.
Endogenous Antibodies That Interfere with ThyroxineFluorescencePolarization Assay but Not with Radioimmunoassay or EMIT1M
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We have identified an individual whose thyroxine (T4) concentration was undetectable with Abbott's fluorescence polarization immunoassay (FPIA) but within the reference range by radioimmunoassay or EMIT' (Syva). The patient's thyrotropin, triiodothyronine, and T-uptake values were within the normal range. The T4 concentration measured by FPIA increased to normal when the immunoglobulinfraction was selectively removed from the serum. When the patient's immunoglobulinfraction was added to normal serum, the T4 content of the normal serum measured by FPIA became falsely low. The patient's antibody interfered with the T4 FPIA by binding to the fluorescein-T4 conjugate. The T-uptake was less affected by the patient's serum because of the low affinity of the patient's antibody to fluorescein-T4 (K = 3.5 x 1Q8 L/mol). The patient's immunoglobulinbound preferentially to fluorescein-T4, in comparison with binding to fluorescein or T4 alone. We conclude that the patient's immunoglobulin bound to an epitope unique to the fluoresceinconjugated T4. Identification of the factors interfering with the FPIA determination ofT4 would be of interest because proper precautions such as modification of the assay could prevent the expensive and extensive patient work-up that has followed these spurious determinations (4). In this study, we identified a novel circulating antibody in a patient's serum that was responsible for falsely low T4 determinations by the FPIA.
MaterIals and Methods

Patient's Medical History
The individual is a 44-year-old man who presented to his physician for an annual routine medical examination required by his employer. He had never been diagnosed with thyroid disease and had no known history of neck injury, exposure to thyroid medication or radiographic contrast agents, or occupational exposure to iodinated chemicals. Prior thyroid-function tests of the patient had normal results. At the time of examinntion, the patient was not taking medication.
His thyroid gland was normal size, his blood pressure was 130/80 mmHg, and his pulse was 60/mm. thyrotropin (TSH) were determined with the microparticle enzyme immunoassay from Abtracer, we also performed the above procedure with normal sera, to which fluorescein-T4 label had been added before and after polyethyleneglycolprecipitation, respectively.
Methods
Quenching of the fluorescent signal by T4 was ruled out by determining the total fluorescence of the added tracer as mentioned above after various concentrations ofT4 were added to normal sera.
The concentration of fluorescein-T4 conjugate from the IMx reagent kit was determined with the Magic T4 RIA (immunoreactive T4 concentration in T-bottle, IMx reagent pack: 171.2 nmol/L).
Results and Discussion
At the time of the patient's presentation, various tests measuring the thyroid function were performed. TSH, T3, and T-uptake determined in the patient's serum were within their normal ranges (1.5 mJU/L, 1300 ng/L, and 47%, respectively). Values for T3-uptake and TBG by RIA were moderatelyabnormal (36%, normal: 22-35; and 13 mg/L, normal: 16-34). However, total 'F4 determined with FPIA was undetectable. An erroneous T4 determination was suspected, and total T4 measurement was repeated by using two other methods. The total T4 concentrations measured by EMiT Falsely low T4 valuesdetermined by inhibition-type RIAs have been previously described to be due toendogenous autoantibodies against T4 and T3 (6,7). The FPIA is an inhibition-type assay similar to the RIA. In this assay, endogenous T4 competeswith fluorescein-labeled T4 fora limited number ofantibody-binding sites. Binding ofthe antibodyto the labelincreases the polarizationoflight emitted from fluore8cein-T4. The amount of polarized lightemitted from the fluorescein-T4 The Scatchard plot was generated by adding 50-200
MLof fluorescein-T4 to the patient's serum and pretreatment solution. A total volume of 380 ML was precipitated with 0.9 mL of polyethylene glycol solution.
To determine the amount of fluorescence that was nonspecifically precipitated with polyethylene glycol that the patient's immunoglobulin bound directly to the fluorescein-T4 tracer.
Once the mechanism of interference had been identified, we tried to determine to which site on the fluorescein-T4 molecule the patient's antibody bound. Our preliminary results suggested that the patient's antibody was different from previously described autoantibodies for T3 and T4 (6, 7). This conclusion was based on the observation that total T4 was measurable by two other methods. Competition experiments of fluorescein-T4 with T4 and T3 demonstrated that the patient's immunoglobulin bound preferentially to fluorescein-T4 patient were within the normal range. (Figure 2 ). These results demonstrate that the binding site for the patient's immuneglobulin is specific fora site generated by the linkage of fluorescein toT4.
A case ofa falsely low total T4 result determined with theFPIA has been previously reported (4). As with our patient, discordant T4 results by FPIA and RIA had been obtained in a euthyroidpatient. If endogenous antibody against fluorescein-T4 was responsible forthe interference observed with the T4 FPIA in these patients, the antibody should obviously also affect the T-uptake measurement.
This was suggested by the authors of the previous study (4), on the assumption that the fluorescein-T4 used inthe 'F-uptake FPIA was identical to the label used in the T4 FPIA.
Paradoxically, the T-uptake resultsfortheirpatientand our -99% ofT4 in the circulation is bound to binding proteins, of which 70% is presented by TBG., The T-uptake FPIA measures the binding of fl#{252}orescein-T4 to these proteins. At equilibrium, the binding of fluorescein-T4 to TBG vs the binding of the label to the patient's imniunoglobulin fraction depends on the affinity of TBG and the antibody to the tracer. This may be estimated by the association constants of TBG (K) and of the patient's IgG (K) to the tracer. At equilibrium, a major interference with the T-uptake should be observed only if the K is greater than K.
As Figure 2 shows, K (3.5 x iO L/mol) was one magnitude lower than the value (2.5 x 10#{176} to 9.1 x 10#{176} L/mol) previously determined forT4 and TBG (8, 9). Provided that the association constants of TBG to fluorescein-T4 and TBG to T4 are similar, the patient's antibody would affect the T-uptake FPIA less than the T4 FPIA.
Such a minor interference with the T-uptake was measured in the patient's sample. When the T-uptake result in our patient was compared with the T3-uptake and TBG determinations by RIA (see above), discrepant results were observed. Furthermore, the addition of the patient's immunoglobulin fraction to normal sera decreased the T-uptake by -20% ( Table 1) . These results suggest that the patient's antibody interfered with the T-uptake FPIA as well.
In summary, we have identified a serum sample containing antibody against fluorescein-T4 that was responsible for falsely low T4 determinations with the FPIA. This antibody appears to have an affinity to fluorescein-T4 such that it affects the T4 FPIA more than the T-uptake FPIA. The antibody differs from other immunoglobulins binding to T3 or 'F4 (6, 7), because it specifically binds to the label used in the Abbott FPIA. Low T4 values due to such interfering antibodies may be suspected if mi1ng a patient's serum with normal serum does not result in an appropriate increase of T4 determined with the FPIA.
